Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Preferred Stock Liabilities: 2012-2023

Historic Preferred Stock Liabilities for Gyre Therapeutics (GYRE) over the last 1 years, with Dec 2023 value amounting to $64.5 million.

  • Gyre Therapeutics' Preferred Stock Liabilities rose 93.72% to $64.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $64.5 million, marking a year-over-year increase of 93.72%. This contributed to the annual value of $64.5 million for FY2023, which is 93.72% up from last year.
  • According to the latest figures from Q4 2023, Gyre Therapeutics' Preferred Stock Liabilities is $64.5 million, which was up 93.72% from $33.3 million recorded in Q2 2023.
  • In the past 5 years, Gyre Therapeutics' Preferred Stock Liabilities registered a high of $64.5 million during Q4 2023, and its lowest value of $33.3 million during Q4 2022.
  • For the 2-year period, Gyre Therapeutics' Preferred Stock Liabilities averaged around $41.1 million, with its median value being $33.3 million (2023).
  • Data for Gyre Therapeutics' Preferred Stock Liabilities shows a peak YoY surged of 93.72% (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Gyre Therapeutics' Preferred Stock Liabilities stood at $33.3 million in 2022, then soared by 93.72% to $64.5 million in 2023.
  • Its Preferred Stock Liabilities was $64.5 million in Q4 2023, compared to $33.3 million in Q2 2023 and $33.3 million in Q1 2023.